New collagen injection aims to smooth wrinkles and plump skin

NCT ID NCT07413445

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early trial tests an injectable collagen-based product called MEC REGENERATE® in 20 adults aged 35–65 with skin laxity, mid-face volume loss, or wrinkles. Participants receive a single injection session, and researchers check safety and skin hydration after 60 days. The goal is to see if the product is safe and may improve skin appearance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Injectable recombinant collagen-based product

What this could lead to

If it works, this could point toward a non-surgical option to temporarily improve skin hydration and reduce wrinkles.

What could go wrong

This is a very small, early study with only 20 people and no control group. Results may not apply to the general population, and long-term safety or effectiveness is unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LAXITY; SKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutis laxa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico

    Genova, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••